Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Paul Phojanokong"'
Autor:
Arun P. Wiita, Elliot Stieglitz, Aashish Manglik, Ansuman T. Satpathy, Byron C. Hann, Faranak Fattahi, Veronica Steri, Paul Phojanokong, Anne Deucher, Jonathan Ramirez, Kevin R. Parker, Sagar P. Bapat, Jeffrey D. Whitman, Kristie L. White, Makeba Marcoulis, Jose M. Rivera, Yu-Hsiu T. Lin, Neha Paranjape, Huimin Geng, Kamal Mandal, Matthew A. Nix
Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis KMT2A/MLL1-rearranged (MLLr) B-cell acute lymphobla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eda55a5274e3677f255a2fad22066d9
https://doi.org/10.1158/2159-8290.c.6548995.v1
https://doi.org/10.1158/2159-8290.c.6548995.v1
Autor:
Arun P. Wiita, Elliot Stieglitz, Aashish Manglik, Ansuman T. Satpathy, Byron C. Hann, Faranak Fattahi, Veronica Steri, Paul Phojanokong, Anne Deucher, Jonathan Ramirez, Kevin R. Parker, Sagar P. Bapat, Jeffrey D. Whitman, Kristie L. White, Makeba Marcoulis, Jose M. Rivera, Yu-Hsiu T. Lin, Neha Paranjape, Huimin Geng, Kamal Mandal, Matthew A. Nix
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071cd4a9ceee3e0f3be7d0956260a267
https://doi.org/10.1158/2159-8290.22539136.v1
https://doi.org/10.1158/2159-8290.22539136.v1
Autor:
Arun P. Wiita, Elliot Stieglitz, Aashish Manglik, Ansuman T. Satpathy, Byron C. Hann, Faranak Fattahi, Veronica Steri, Paul Phojanokong, Anne Deucher, Jonathan Ramirez, Kevin R. Parker, Sagar P. Bapat, Jeffrey D. Whitman, Kristie L. White, Makeba Marcoulis, Jose M. Rivera, Yu-Hsiu T. Lin, Neha Paranjape, Huimin Geng, Kamal Mandal, Matthew A. Nix
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d17db5e546d5631791798d1c469ce4
https://doi.org/10.1158/2159-8290.22539127
https://doi.org/10.1158/2159-8290.22539127
Autor:
Kamal Mandal, Jeffrey D. Whitman, Kevin R. Parker, Elliot Stieglitz, Faranak Fattahi, Aashish Manglik, Jonathan Ramirez, Veronica Steri, Yu-Hsiu T. Lin, Ansuman T. Satpathy, Anne Deucher, Makeba Marcoulis, Matthew A. Nix, Huimin Geng, Paul Phojanokong, Arun P. Wiita, Sagar P. Bapat, Byron Hann, Kristie L. White, Neha Paranjape, Jose M. Rivera
Publikováno v:
Cancer Discovery. 11:2032-2049
Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis KMT2A/MLL1-rearranged (MLLr) B-cell acute lymphobla
Autor:
Matthew A, Nix, Kamal, Mandal, Huimin, Geng, Neha, Paranjape, Yu-Hsiu T, Lin, Jose M, Rivera, Makeba, Marcoulis, Kristie L, White, Jeffrey D, Whitman, Sagar P, Bapat, Kevin R, Parker, Jonathan, Ramirez, Anne, Deucher, Paul, Phojanokong, Veronica, Steri, Faranak, Fattahi, Byron C, Hann, Ansuman T, Satpathy, Aashish, Manglik, Elliot, Stieglitz, Arun P, Wiita
Publikováno v:
Cancer Discov
Alternate strategies are needed for B-cell malignancy patients relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis KMT2A/MLL1-rearranged (MLLr) B-ALL, which we further found